Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality

References

• Sand MS, Fisher W, Rosen R, et al. Erectile dysfunction and constructs of masculinity and quality of life in the multinational Men's Attitudes to Life Events and Sexuality (MALES) study. J Sex Med. 2008;5:583–594.
   PubMed Web of Science ®Google Scholar
• Laumann EO, West S, Glasser D, et al. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65.
   PubMed Web of Science ®Google Scholar
• Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–157.
   PubMed Web of Science ®Google Scholar
• Pallangyo P, Nicholaus P, Kisenge P, et al. A community-based study on prevalence and correlates of erectile dysfunction among Kinondoni District Residents, Dar Es Salaam, Tanzania. Reprod Health. 2016;13:140.
   PubMed Web of Science ®Google Scholar
• Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34:1185–1192.
   PubMed Web of Science ®Google Scholar
• Omland T, Randby A, Hrubos-Str⊘m H, et al. Relation of erectile dysfunction to subclinical myocardial injury. Am J Cardiol. 2016;118:1821–1825.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65:968–978.
   PubMed Web of Science ®Google Scholar
• Jackson G, Nehra A, Miner M, et al. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J Clin Pract. 2013;67:1163–1172.
   PubMed Web of Science ®Google Scholar
• Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future cardiovascular events. Circulation. 2018;138:540–542.
   PubMed Web of Science ®Google Scholar
• Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766–778.
   PubMed Web of Science ®Google Scholar
• Yao FJ, Zhang YD, Wan Z, et al. Erectile dysfunction is associated with subclinical carotid vascular disease in young men lacking widely-known risk factors. Asian J Androl. 2018;20:400–404.
   PubMed Web of Science ®Google Scholar
• Osondu CU, Vo B, Oni ET, et al. The relationship of erectile dysfunction and subclinical cardiovascular disease: a systematic review and meta-analysis. Vasc Med. 2018;23:9–20.
   PubMed Web of Science ®Google Scholar
• Chiurlia E, D’Amico R, Ratti C, et al. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46:1503–1506.
   PubMed Web of Science ®Google Scholar
• Corona G, Isidori AM, Aversa A, et al. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med. 2016;13:317–337.
   PubMed Web of Science ®Google Scholar
• Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol. 2007;52:54–70.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Mulay A, et al. Long-term testosterone therapy in type 2 diabetes is associated with decreasing waist circumference and improving erectile function. World J Mens Health. 2018;36:e33.
   Google Scholar
• Hackett G, Cole N, Saghir A, et al. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int. 2016;118:804–813.
   PubMed Web of Science ®Google Scholar
• Permpongkosol S, Khupulsup K, Leelaphiwat S, et al. Effects of 8-year treatment of long-acting testosterone undecanoate on metabolic parameters, urinary symptoms, bone mineral density, and sexual function in men with late-onset hypogonadism. J Sex Med. 2016;13:1199–1211.
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7:2572–2582.
   PubMed Web of Science ®Google Scholar
• Haider KS, Haider A, Doros G, et al. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol. 2018;199:257–265.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Allen KR, Ni X, et al. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011;60:1010–1016.
   PubMed Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165:675–685.
   PubMed Web of Science ®Google Scholar
• Morales A, Bebb RA, Manjoo P, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ 2015;187:1369. Appendix available at http://www.cmaj.ca/content/suppl/2015/10/26/cmaj.150033.DC1/15-0033-1-at.pdf (accessed Jan 10, 2016).
   PubMed Web of Science ®Google Scholar
• Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017;14:1504–1523.
   PubMed Web of Science ®Google Scholar
• Dean JD, McMahon CG, Guay AT, et al. The International Society for sexual medicine’s process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med. 2015;12:1660–1686.
   PubMed Web of Science ®Google Scholar
• Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–135.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Nettleship J, Almehmadi Y, et al. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia. 2016;48:793–799.
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Doros G, et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond). 2016;40:162–170.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581–606.
   PubMed Web of Science ®Google Scholar
• Walle B, Lebeta KR, Fita YD, et al. Prevalence of erectile dysfunction and associated factors among diabetic men attending the diabetic clinic at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia, 2016. BMC Res Notes. 2018;11:130.
   PubMedGoogle Scholar
• Biswas M, Hampton D, Newcombe RG, et al. Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf). 2012;76:665–673.
   PubMed Web of Science ®Google Scholar
• Rezvani MR, Saadatjou SA, Sorouri S, et al. Comparison of serum free testosterone, luteinizing hormone and follicle stimulating hormone levels in diabetics and non-diabetics men – a case–control study. J Res Health Sci. 2012;12:98–100.
   PubMedGoogle Scholar
• Hackett GI, Kell P, Ralph D, et al. Biochemical hypogonadism in men with type 2 diabetes in primary care practice. 2009;9:226–231.
   Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–769.
   PubMed Web of Science ®Google Scholar
• Association American D. Updates to the standards of medical care in diabetes – 2018. Diabetes Care. 2018;41:2045–2047.
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin D, Dorsos A, et al. Most hypogonadal men with type 2 diabetes mellitus (T2DM) achieve HbA1c targets when treated with testosterone undecanoate injections (TU) for up to 12 years. Diabetes. 2017;66:A305. (abstract).
   Web of Science ®Google Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21:158–169.
   PubMed Web of Science ®Google Scholar
• Tan HM, Tong SF, Ho CC. Men’s health: sexual dysfunction, physical, and psychological health-is there a link? J Sex Med. 2012;9:663–671.
   PubMed Web of Science ®Google Scholar
• Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients? Int J Impot Res. 2006;18:55–60.
   PubMed Web of Science ®Google Scholar
• Azab SS, El Din Hosni H, El Far TA, et al. The predictive value of arteriogenic erectile dysfunction for coronary artery disease in men. J Sex Med. 2018;15:880–887.
   PubMed Web of Science ®Google Scholar
• Miner M, Parish SJ, Billups KL, et al. Erectile dysfunction and subclinical cardiovascular disease. Sexual Med Rev. 2018. doi:10.1016/j.sxmr.2018.01.001
   PubMedGoogle Scholar
• Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA Guideline. J Urol. 2018;200:423–432.
   PubMed Web of Science ®Google Scholar
• Zhao L, Song Y, Dong P, et al. Brachial pulse pressure and cardiovascular or all-cause mortality in the general population: a meta-analysis of prospective observational studies. J Clin Hypertens. 2014;16:678–685.
   PubMed Web of Science ®Google Scholar
• Steppan J, Barodka V, Berkowitz DE, et al. Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract. 2011;2011:263585.
   PubMedGoogle Scholar
• Traish AM, Haider A, Haider KS, et al. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther. 2017;22:414–433.
   PubMed Web of Science ®Google Scholar
• Morgunov LY, Denisova IA, Rozhkova TI, et al. Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Aging Male. 2018. doi:10.1080/13685538.2018.1487932
   PubMedGoogle Scholar
• Kloner RA, Carson C, Dobs A, et al. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67:545–557.
   PubMed Web of Science ®Google Scholar
• Yassin A, AlRumaihi K, Alzubaidi R, et al. Testosterone, testosterone therapy and prostate cancer. Aging Male. 2019. doi:10.1080/13685538.2018.1524456
   PubMed Web of Science ®Google Scholar
• Wolf J, Keipert D, Motazedi H, et al. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. Aging Male. 2017;20:225–234.
   PubMed Web of Science ®Google Scholar
• Yassin A, Salman M, Talib RA, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20:125–133.
   PubMed Web of Science ®Google Scholar
• Haider A, Zitzmann M, Doros G, et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year Median Followup of 3 Registries. J Urol. 2015;193:80–86.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981–990.
   PubMed Web of Science ®Google Scholar
• Efesoy O, Apa D, Tek M, et al. The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset hypogonadism. Aging Male. 2016;19:79–84.
   PubMed Web of Science ®Google Scholar
• Ohwaki K, Endo F, Shimbo M, et al. Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male. 2017;20:257–260.
   PubMed Web of Science ®Google Scholar
• Tu H, Gu J, Meng QH, et al. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017;13:1949–1957.
   PubMed Web of Science ®Google Scholar
• Haider A, Cole N, Saghir A, et al. Long-term treatment with testosteroen undecanoate injections sustainably improves erectile function and metabolic control in hypogonadal men with type 2 diabetes mellitus (T2DM). 2015;193:e903–e903.
   Google Scholar